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A B S T R A C T
Background: Diagnostic requests for both Zika virus (ZIKV) and dengue virus (DENV) infections in returning
travelers have signiﬁcantly increased during the recent ZIKV outbreak in the Americás. These ﬂaviviruses have
overlapping clinical syndromes and geographical distribution, but diagnostic diﬀerentiation is important
because of diﬀerent clinical consequences. As ﬂaviviruses are known to have a short viremic period, diagnostics
often rely on serological methods, which are challenging due to extensive cross-reactive antibodies.
Objective: To re-evaluate the performance of DENV serological assays in laboratory conﬁrmed ZIKV-infected
travelers.
Study design: The extent of cross-reactivity of the DENV NS1 antigen, IgM and IgG ELISA was analyzed in 152
clinical blood samples collected from 69 qRT-PCR and 24 virus neutralization titer (VNT) conﬁrmed ZIKV-
infected travelers.
Results: The majority of travelers in the presented cohort returned to the Netherlands from Suriname and
presented with symptoms of fever and rash. Twenty-three percent of the female travelers were pregnant. None of
the 39 ZIKV RNA positive blood samples were cross-reactive in the DENV NS1 antigen ELISA. The rates of cross-
reactivity of the DENV IgM and IgG ELISÁs were 31% and 54%, respectively, after excluding travelers with
(potential) previous DENV exposure.
Conclusions: Although the DENV NS1 antigen assay was highly speciﬁc in this cohort of laboratory conﬁrmed
ZIKV-infected travelers, we demonstrate high percentages of cross-reactivity of DENV IgM and IgG ELISÁs of
which diagnostic laboratories should be aware. In addition, the high rate of DENV IgG background of> 25%
complicates a proper serological diagnosis in this group.
1. Background
The recent outbreak of Zika virus (ZIKV) in the America’s has caused
a signiﬁcant increase in diagnostic requests for both ZIKV and dengue
virus (DENV) infections in travelers returning from endemic regions to
Europe. Both ﬂaviviruses typically cause overlapping symptoms while
co-circulating in large parts of the world which often results in a
combined diagnostic request [1,2].
Serology is an important diagnostic tool to conﬁrm or rule out
DENV and/or ZIKV infection. In most patients, molecular and/or
antigen testing on serum will not suﬃce because of the short duration
of viremia (typically about 3–7 days post onset of symptoms and for
ZIKV possibly longer in pregnant women) [1,3,4]. Reverse-transcriptase
polymerase chain reaction (RT-PCR) on urine or whole blood can
lengthen the detection window of both DENV and ZIKV. Detection
times of up to 15 days post onset of disease in urine have been reported
for both ﬂaviviruses [5–7]. In daily practice however, there is often no
urine available or the delay of sampling is more than 2 weeks post onset
of symptoms. Similarly as has been described for West Nile virus [8],
longer detection times of up to 81 days could be obtained for ZIKV RNA
in whole blood [9], but routine processing of whole blood samples is
often absent in diagnostic work ﬂows of clinical virology laboratories.
Because of the teratogenicity of ZIKV [10], conﬁrming or ruling out
a ZIKV infection is important especially in pregnant women. With an
estimated 80% of ZIKV infections being asymptomatic [11], ZIKV
diagnostics are nowadays often part of routine work-up in healthy
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pregnant women or couples with a desire to have children who have
visited an endemic area. The diagnosis of a ZIKV infection then often
relies on comparative ZIKV and DENV serological methods as the
interpretation of ﬂavivirus serology is complex [12]. Flaviviruses are
known for their antigenic similarity, e.g. the amino acid sequence of the
envelope protein of the DENV serocomplex shows a similarity of
54–59% with that of ZIKV [13]. In humans this is known to trigger a
cross-reactive antibody response, which makes discrimination between
the respective infections by routine serological assays, such as immuno-
ﬂuorescence assay (IFA) and enzyme-linked immunosorbent assay
(ELISA), diﬃcult. Furthermore, a proper interpretation of serology
results is complicated by original antigenic sin in patients with a
secondary ﬂavivirus infection or a previous ﬂavivirus vaccination, as
the highest titer is often found for antibodies directed to the virus or
vaccine of primary exposure [14–16]. Additionally, the close relation-
ship between ZIKV and DENV was highlighted by the observation of
antibody-dependent enhancement of ZIKV replication in in vitro studies
with pooled convalescent serum collected from subjects who recovered
from infection with DENV [17].
Since the start of the ZIKV outbreak in the Americás in May 2015
much attention has been paid to the evaluation of the speciﬁcity and
sensitivity of diﬀerent ZIKV serological assays [18–21] while reassess-
ment of routine DENV serological tests has been neglected. In the
current era it is therefore necessary to re-evaluate the previously
implemented serodiagnostics for DENV. We reassessed our routine
DENV serology in the scope of potentially cross-reactive ZIKV antigen
and antibodies using an anonymized cohort of 93 ZIKV-infected
travelers returning to the Netherlands.
2. Objectives
We re-evaluated i) the speciﬁcity of the Platelia™ DENV NS1 antigen
ELISA in ZIKV viremic travelers and ii) the speciﬁcity of the Euroimmun
DENV IgM and IgG ELISA by assessing the extent of cross-reactivity in
blood samples of laboratory conﬁrmed ZIKV-infected travelers.
3. Study design
From December 2015 to October 2016 the Viroscience laboratory at
Erasmus University Medical Center (Rotterdam, the Netherlands)
diagnosed ZIKV infection in 93 returning travelers who had visited a
ZIKV endemic region. For analysis in this study, all patient samples
were anonymized according to medical ethical regulations. ZIKV
infection was conﬁrmed in 69 patients by an ISO15189:2012 validated
in-house real-time semi-quantitative (q)RT-PCR using the E-set
(1086–1162) of Lanciotti et al. [22] on EDTA-plasma, serum or urine.
Forty-seven patients had ZIKV viremia, and in 24 cases a follow-up
serum was available (Fig. 1A). Twenty-two patients were diagnosed by
a positive qRT-PCR on urine. For all of them a serum sample of the same
collection date as the urine sample was available, while for 11 of them a
follow-up serum was available as well (Fig. 1A). Additionally, ZIKV
infection was diagnosed in 24 travelers with acute-convalescent phase
serum pairs, based on the presence of ZIKV neutralizing antibodies in
convalescent serum samples (Fig. 1B). ZIKV virus neutralization was
carried out as follows: two-fold serum dilutions were incubated with
100 TCID50 of Zika virus Suriname strain 2016 (Genbank reference
KU937936) at 37 °C and then used to inoculate Vero cells for 5 days at
37 °C. ZIKV infection was read out under the microscope by cytopathic
eﬀect. A reciprocal VNT ZIKV immunoglobulins (Ig) titer of≥1/32 was
considered positive.
In total, 152 blood samples from 93 patients were available for
reassessment of DENV serology tests (Fig. 1A and B). Speciﬁcity of the
DENV NS1 antigen ELISA (Platelia™ Enzym Immunoassay, Biorad,
Hercules, CA, USA) was assessed using 39 out of 47 viremic samples
(i.e., plasma or serum ZIKV qRT-PCR positive) of which suﬃcient
volume was left (Fig. 1A). The speciﬁcity of the DENV IgM and IgG
ELISÁs (Euroimmun, Lübeck, Germany) was re-evaluated by assessing
the extent of cross-reactivity in relation to the Euroimmun ZIKV IgM
and IgG ELISA results on ﬁrst and follow-up samples of qRT-PCR or
VNT conﬁrmed ZIKV-infected travelers. IgM and IgG cross-reactivity
were deﬁned as a positive ZIKV IgM/G result in combination with a
positive or equivalent DENV IgM/G result. We did not include any ZIKV
IgM/IgG equivalent sera in our cross-reactivity analysis, since we would
like to measure all possible DENV IgM and IgG cross-reactive antibodies
(i.e., both equivalent and positive DENV signals) only in samples with
clearly positive ZIKV IgM/IgG signals. An equivalent IgM/G ELISA
result was deﬁned as 0.8≥ signal to cut-oﬀ ratio< 1.1. All ELISÁs
were performed as described by the manufactureŕs instructions guide.
4. Results
4.1. Cohort description
Table 1 describes the clinical characteristics of the 93 laboratory
conﬁrmed ZIKV-infected returning travelers. The majority of them
returned from Suriname (50%) and Dominican Republic (16%). The
most common reported symptoms were fever (60%) and rash (70%),
sometimes in combination with arthralgia (41%) and/or conjunctivitis
(25%). Symptoms were unknown in 13% and 9% of the travelers were
asymptomatic. A previous history of dengue fever or other ﬂavivirus
infection and/or vaccination was unknown for all travelers. Flavivirus
infections, besides DENV, were not systematically ruled out. The
median time of known days between onset of disease and diagnostics
was 4 days (range of 1–36 days) in 46 travelers (Table 1).
4.1.1. Speciﬁcity of DENV NS1 antigen ELISA
The Platelia™ DENV NS1 antigen ELISA appeared to be 100%
speciﬁc using a cohort of 39 ZIKV-RNA positive samples. All of these
viremic samples tested negative. As far as known, these samples were
taken ≤11 days post onset of disease (< 5 days: N = 17; 5–10 days:
N = 3; 11 days: N = 1; and unknown number of days post onset of
disease: N = 18).
4.1.2. Speciﬁcity of DENV IgM and IgG ELISA
To exclude potential co-infections with DENV, ﬁrst of all the
Platelia™ DENV NS1 antigen ELISA was performed in all ﬁrst samples
where possible (N = 84, in 9 samples there was insuﬃcient volume left
for this test). None of these 84 ﬁrst samples were NS1 antigen positive.
The sensitivity and speciﬁcity of the Platelia™ NS1 antigen ELISA vs.
our in-house DENV type 1–4 qRT-PCR [23,24] in a retrospective cohort
of 141 returning travelers clinically suspected for DENV infection were
100% (95% Conﬁdence Interval (CI): 94.4–100%) and 90.8% (95% CI:
82.2–95.5%), respectively. Finally, all ﬁrst 93 and 59 available follow-
up blood samples were used for calculation of the extent of DENV IgM
cross-reactivity (Fig. 1A and B).
To deﬁne IgG cross-reactivity we excluded patients in whom
previous DENV exposure could not be ruled out. Twenty-ﬁve out of
93 (27%) travelers already had DENV IgG antibodies in their ﬁrst serum
while the ZIKV IgG result was negative. Forty-ﬁve patients out of 93
(48%) presented with both ZIKV and DENV IgG antibodies in their ﬁrst
serum. In these 70 travelers it is thus impossible to discriminate if
reactivity in the DENV ELISA is detected due to the actual presence of
pre-existing DENV speciﬁc antibodies or due to cross-reactive ZIKV IgG
antibodies of the present infection. To prevent bias from these
detectable DENV IgG antibodies all these cases (i.e., with a positive
or equivalent DENV IgG result in their ﬁrst serum) were excluded from
the IgG cross-reactivity analysis leaving 23 patients with 35 sera to
consider (Fig. 1A and B).
Table 2A summarizes the DENV IgM and IgG results vs. ZIKV IgM
and IgG results from qRT-PCR conﬁrmed ZIKV-infected patients,
divided in subcategories of samples drawn<5 days, 5–10 days, > 10
days and an unknown number of days post onset of disease. These
M.P.A. van Meer et al. Journal of Clinical Virology 92 (2017) 25–31
26
subcategories were based on known kinetics of antibodies in other
ﬂaviviruses like DENV [25] and West Nile virus [26]. The percentages
of ZIKV IgM and IgG antibodies that were cross-reactive in the DENV
IgM and IgG ELISA were 33% (13/39) and 50% (5/10), respectively.
Table 2B shows the DENV IgM and IgG results vs. ZIKV IgM and IgG
results in VNT conﬁrmed travelers. Percentages of DENV IgM and IgG
cross-reactivity in this group were comparable, i.e., 20% (2/10) and
67% (2/3), respectively. After combining the samples from ZIKV qRT-
PCR and VNT conﬁrmed infected travelers the total rates of DENV IgM
and IgG cross-reactivity were 31% (15/49) and 54% (7/13), respec-
tively.
After excluding the 70 cases with a DENV positive or equivalent
result in their ﬁrst serum, there remained 12 out of 23 cases (N = 10
ZIKV qRT-PCR and N = 2 VNT conﬁrmed) from whom a follow-up
serum was available (Fig. 1) which allowed more detailed analysis.
Their clinical characteristics together with the performed ZIKV qRT-
PCR and VNT diagnostics are summarized in the context of the ZIKV
and DENV ELISA results (Table 3). In these DENV naive patients, IgG
cross-reactivity in the DENV ELISA was observed in seven out of 13 sera
(54%) in which ZIKV IgG antibodies were detected, representing 11
travelers. ZIKV VNT was positive in two patients (case 2 and case 12)
with equivalent and in one patient (case 6) with negative ZIKV IgG
ELISA results, while corresponding DENV IgG results were negative
(Table 3). These three sera were not included in the IgG cross-reactivity
analysis, since the percentage of cross-reacting IgG antibodies in the
DENV ELISA was solely calculated with respect to the ZIKV IgG ELISA
positive samples.
5. Discussion
The presented data in this study demonstrated a 100% speciﬁcity of
DENV NS1 antigen ELISA testing in 39 ZIKV viremic blood samples. A
Fig. 1. Overview of performed DENV and ZIKV serology tests on blood samples, drawn < 5 days, 5–10 days,> 10 days and an unknown (UK) number of days post onset of disease, from
69 qRT-PCR (A) and 24 Ig VNT (B) conﬁrmed ZIKV-infected travelers. FU: follow-up; pos: positive; eq: equivalent.
Table 1
Characteristics of 93 travelers with a laboratory conﬁrmed ZIKV infection.
qRT-PCR
positive
(N = 69)
Ig VNT positive
(N = 24)
Male 22 (32%) 5 (21%)
Female 47 (68%) 19 (79%)
Mean age ± SD (years) 46.9 ± 14.6 37.0 ± 11.4
Pregnant? (N) (% of female) 4 (9%) 11 (58%)
Travel history (N)
Suriname 36 (52%) 10 (42%)
Dominican Republic 11 (16%) 4 (17%)
Nicaragua 3 (4%) 0 (0%)
Unknown 6 (9%) 4 (17%)
Other 13 (19%)b 6 (25%)c
Symptomatic (N)a 60 (87%) 13 (54%)
fever (% of symptomatic) 34 (57%) 10 (77%)
rash 45 (75%) 6 (46%)
arthralgia 27 (45%) 3 (23%)
conjunctivitis 17 (28%) 1 (8%)
Asymptomatic (N) 2 (3%) 6 (25%)
Symptoms unknown (N) 7 (10%) 5 (21%)
Median time in days (range) between
onset of disease and ﬁrst serum
(number of patients)
3 (1–24)
(N = 38)
10 (3–36)
(N = 8)
Follow-up serum available? (N) 35 (51%) 24 (100%)
Median interval time in days (range)
between ﬁrst and follow-up serum
19 (6–67) 20.5 (10–70)
a Less frequently reported symptoms in all travelers were: myalgia, headache, malaise,
lymphadenopathy, nausea, diarrhoea, sore throat, oedema and pruritus.
b Other countries: N = 2: Barbados and St. Maarten; N = 1: Aruba, Brazil, Cape Verde,
Cayman Islands, Costa Rica, Curaçao, Martinique, St. Lucia and Venezuela.
c Other countries: N = 1: Brazil, Curaçao, El Salvador, Panama, Thailand and
Venezuela.
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Table 2
A. DENV and corresponding ZIKV IgM (left) and IgG (right) ELISA results in 104 and 31 samples from 69 and 21 ZIKV qRT-PCR conﬁrmed infected travelers, respectively. Samples with
cross-reactive ZIKV antibodies in the DENV ELISA are highlighted in red. B. DENV and corresponding ZIKV IgM (left) and IgG (right) ELISA results in 48 and 4 samples from 24 and 2 ZIKV
Ig VNT conﬁrmed infected travelers, respectively. Samples with cross-reactive ZIKV antibodies in the DENV ELISA are highlighted in red.
A.
B.
p.o.d.: post onset of disease; pos: positive; eq: equivalent; neg: negative.
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recent case report by Gyurech et al. [27] described a false positive
DENV NS1 antigen test result in a patient with an acute ZIKV infection,
who was initially suspected for acute dengue fever. Notably, the false
positive DENV NS1 result was only found when applying the SD Bioline
Dengue Duo rapid immunochromatographic NS1 antigen test (ICT)
(Standard Diagnostics, South Korea) and not when applying the Biorad
NS1 antigen strip or Biorad Platelia™ NS1 antigen ELISA that was
assessed here. In accordance, a recent retrospective study by Matheus
et al. [28] did not show any DENV NS1 antigen cross-reactivity in 65
qRT-PCR conﬁrmed acute ZIKV samples of French Guiana in neither the
SD Bioline Dengue Duo ICT nor the Biorad Platelia™ ELISA.
The total rate of DENV IgM cross-reactivity after combining the
samples from qRT-PCR and VNT conﬁrmed ZIKV-infected travelers was
31% (15/49). Although it has been reported that ZIKV-speciﬁc-IgM
generally appears around 5 days post onset of disease [21], the majority
of ZIKV IgM positive and equivalent samples in this cohort were
drawn>10 days post onset of disease. A speciﬁc period post onset of
disease for occurrence of cross-reactive IgM antibodies could therefore
not be derived. Furthermore, it should be noted that for 7 of the 15
DENV IgM positive sera a ZIKV − DENV co-infection could not be
excluded by DENV NS1 antigen ELISA as either the sampling day post
onset of symptoms was unknown and/or a the ZIKV infection was
conﬁrmed based on solely a qRT-PCR positive urine (n = 5) or positive
VNT (n = 2). Nevertheless, DENV RNA type 1–4 was not detected in
these ﬁve urine samples (n = 1 taken 8 days p.o.d. and in n = 4
unknown). In the 2 VNT positive cases ﬁrst sera were drawn at 9 and
10 days post onset of symptoms which is too late for testing for acute
DENV infection by NS1 antigen ELISA or DENV qRT-PCR. Although
Table 3
Characteristics of 12 DENV naive travelers with ZIKV infection and corresponding results of ZIKV and DENV ELISÁs. Sera with cross-reactive ZIKV IgG antibodies in the DENV ELISA are
highlighted in red.
Neg: negative; Pos: positive; Equiv: equivalent; M: male; F: female; N.A.: non applicable.
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ZIKV-DENV co-infections have only been occasionally reported [29–31]
the prevalence could be underestimated due to the high rate of
asymptomatic infections with both ﬂaviviruses, similar clinical symp-
toms and/or lack of concurrent testing.
Within the presented cohort 27% of the travelers has IgG antibodies
against DENV before they develop IgG antibodies against ZIKV,
indicating that a substantial part of the potential cross-reactive ZIKV
IgG antibodies in the DENV ELISA can likely be attributed to back-
ground DENV IgG antibodies. After eliminating these samples, the
Euroimmun IgG DENV ELISA was cross-reactive in 54% (7 out of 13) of
blood samples of conﬁrmed ZIKV-infected patients, who were DENV
IgG naive at their ﬁrst presentation. As expected, all DENV IgG cross-
reactive samples occurred> 10 days in the group of travelers with
known date of onset of symptoms. This emphasizes the importance of
molecular diagnostics on preferably acute samples in ZIKV diagnostics,
in particular because original antigenic sin may boost the (neutralizing
antibody) titer against other ﬂaviviruses to which the person previously
was exposed even to a factor four-fold in paired serum samples [32].
Current developments indicate that the sensitivity of ZIKV diagnostics
can be increased by molecular testing in urine, saliva, semen and whole
blood in combination with analysis of serum.
To discriminate between cross-reactive ZIKV antibodies and boosted
DENV antibodies from a previous infection, comparative VNT’s should
ideally be performed against ZIKV and DENV type 1–4 (or the speciﬁc
ﬂaviviruses endemic to the region of exposure [12]), as recently
suggested in CDC Morbidity and Mortality Weekly report [21].
Unfortunately, even in VNT’s cross-reactivity has been observed and
most routine diagnostic laboratories will not have the capacity to
perform VNT and thus are dependent on available commercial assays.
In conclusion, we have demonstrated that the recent ZIKV outbreak
in Latin America substantially aﬀects the DENV serology in routine
diagnostic laboratories. We conﬁrmed a high speciﬁcity of DENV NS1
antigen but showed that in our cohort of 93 travelers with conﬁrmed
ZIKV infection, about one third of ZIKV IgM and more than half of ZIKV
IgG antibodies cross-reacted in the Euroimmun DENV ELISA.
Diagnostics are complicated by the observed high rates of DENV IgG
background in this group of returning travelers of which clinical
laboratories should be aware. It is therefore recommended to: i)
promote early sampling enabling DENV NS1 antigen and ZIKV and
DENV qRT-PCR testing, ii) always perform ZIKV and DENV serology in
parallel enabling more informative comparative serology iii) include,
when available, virus neutralization in paired samples in high risk
groups for adverse infection, like pregnant women, and iv) be aware of
high rates of cross-reactivity in routine DENV IgM and IgG serology in
an increasing number of returning travelers who can present with an
acute or past ZIKV infection.
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